Literature DB >> 9137986

Bisphosphonates: mechanisms of action and clinical use in osteoporosis--an update.

H Fleisch1.   

Abstract

Bisphosphonates are a new class of compounds with the ability to decrease bone resorption. Their mode of action appears to be complex, involving both a direct effect on the osteoclasts and an indirect one through osteoblasts. They are currently the drugs of choice in humans for Paget's disease and tumor bone disease, and are most useful in various types of osteoporosis. In view of their low toxicity, they are a most valuable addition to our therapeutic possibilities in the treatment of bone diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9137986     DOI: 10.1055/s-2007-979008

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

Review 1.  Novel host response therapeutic approaches to treat periodontal diseases.

Authors:  Keith L Kirkwood; Joni A Cirelli; Jill E Rogers; William V Giannobile
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

2.  Further hearing loss during osteoporosis treatment with etidronate.

Authors:  S Yaşil; A Cömlekçi; A Güneri
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

3.  Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.

Authors:  Keiichiro Kimachi; Hiroshi Kajiya; Shuji Nakayama; Tetsuro Ikebe; Koji Okabe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-12       Impact factor: 3.000

Review 4.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

5.  Effect of renal function on risedronate pharmacokinetics after a single oral dose.

Authors:  D Y Mitchell; J V St Peter; R A Eusebio; K A Pallone; S C Kelly; D A Russell; J D Nesbitt; G A Thompson; J H Powell
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

6.  RANKL inhibition through osteoprotegerin blocks bone loss in experimental periodontitis.

Authors:  Qiming Jin; Joni A Cirelli; Chan Ho Park; James V Sugai; Mario Taba; Paul J Kostenuik; William V Giannobile
Journal:  J Periodontol       Date:  2007-07       Impact factor: 6.993

7.  Bilateral atypical femoral fractures in a patient with multiple myeloma treated with intravenous bisphosphonate therapy.

Authors:  Ichiro Tonogai; Tomohiro Goto; Daisuke Hamada; Toshiyuki Iwame; Shinji Yoshioka; Takahiko Tsutsui; Yuichiro Goda; Hiroshi Egawa; Koichi Sairyo
Journal:  Case Rep Orthop       Date:  2014-07-22

8.  Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival.

Authors:  O Fromigue; N Kheddoumi; J-J Body
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.